- Home
- ADTX vs SCNI Comparison
ADTX vs SCNI Comparison
Compare ADTX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- SCNI
- Stock Information
- Founded
- ADTX 2017
- SCNI 2003
- Country
- ADTX United States
- SCNI Israel
- Employees
- ADTX N/A
- SCNI N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADTX Health Care
- SCNI Health Care
- Exchange
- ADTX Nasdaq
- SCNI Nasdaq
- Market Cap
- ADTX 3.1M
- SCNI 3.2M
- IPO Year
- ADTX 2020
- SCNI N/A
- Fundamental
- Price
- ADTX $1.21
- SCNI $2.62
- Analyst Decision
- ADTX
- SCNI
- Analyst Count
- ADTX 0
- SCNI 0
- Target Price
- ADTX N/A
- SCNI N/A
- AVG Volume (30 Days)
- ADTX 1.2M
- SCNI 1.1M
- Earning Date
- ADTX 08-18-2025
- SCNI 08-14-2025
- Dividend Yield
- ADTX N/A
- SCNI N/A
- EPS Growth
- ADTX N/A
- SCNI N/A
- EPS
- ADTX N/A
- SCNI N/A
- Revenue
- ADTX $55,323.00
- SCNI $658,000.00
- Revenue This Year
- ADTX $15,768.94
- SCNI N/A
- Revenue Next Year
- ADTX N/A
- SCNI N/A
- P/E Ratio
- ADTX N/A
- SCNI N/A
- Revenue Growth
- ADTX N/A
- SCNI N/A
- 52 Week Low
- ADTX $1.11
- SCNI $1.90
- 52 Week High
- ADTX $27,200.00
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- ADTX 34.54
- SCNI 44.75
- Support Level
- ADTX $1.28
- SCNI $2.14
- Resistance Level
- ADTX $2.19
- SCNI $2.60
- Average True Range (ATR)
- ADTX 0.17
- SCNI 0.16
- MACD
- ADTX 0.04
- SCNI 0.00
- Stochastic Oscillator
- ADTX 9.26
- SCNI 34.78
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.